{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["27(2)"],"submitter":["Dragos F"],"pubmed_abstract":["This systematic review examines chronic kidney disease-associated pruritus (CKD-aP) as a complex clinical manifestation in patients undergoing hemodialysis. Traditionally considered a secondary symptom of end-stage renal disease, emerging evidence now positions CKD-aP as a multidimensional disorder with substantial pathogenic influence on patient outcomes. Using the PRISMA 2020 methodology, we critically evaluated 54 peer-reviewed studies published between 2020 and 2025. Our synthesis highlights a convergence of five mechanistic frameworks underpinning CKD-aP: elevated levels of uremic toxins originating from gut microbial dysbiosis, immune activation driven by IL-31 and other pro-inflammatory cytokines, heightened peripheral and central neural sensitization, dysregulation of endogenous op"],"journal":["International journal of molecular sciences"],"pagination":["851"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12840920"],"repository":["biostudies-literature"],"pubmed_title":["Chronic Kidney Disease-Associated Pruritus in Hemodialysis: Unraveling Mechanisms and Emerging Therapeutic Targets-A Systematic Review."],"pmcid":["PMC12840920"],"pubmed_authors":["Dragos F","Gabriel PF","Tatiana C","Luana A","Florentin PM","Bogdan C","Tony H","Iulian M","Mihaela ML","Georgeta Camelia C","Adrian NR","Liliana-Ana T","Andreea A","Livia SI","Iuliana-Cezara T","Florin-Daniel E","Daria AM","Stere P"],"additional_accession":[]},"is_claimable":false,"name":"Chronic Kidney Disease-Associated Pruritus in Hemodialysis: Unraveling Mechanisms and Emerging Therapeutic Targets-A Systematic Review.","description":"This systematic review examines chronic kidney disease-associated pruritus (CKD-aP) as a complex clinical manifestation in patients undergoing hemodialysis. Traditionally considered a secondary symptom of end-stage renal disease, emerging evidence now positions CKD-aP as a multidimensional disorder with substantial pathogenic influence on patient outcomes. Using the PRISMA 2020 methodology, we critically evaluated 54 peer-reviewed studies published between 2020 and 2025. Our synthesis highlights a convergence of five mechanistic frameworks underpinning CKD-aP: elevated levels of uremic toxins originating from gut microbial dysbiosis, immune activation driven by IL-31 and other pro-inflammatory cytokines, heightened peripheral and central neural sensitization, dysregulation of endogenous op","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-09T03:17:56.378Z","creation":"2026-06-09T03:11:43.242Z"},"accession":"S-EPMC12840920","cross_references":{"pubmed":["41596500"],"doi":["10.3390/ijms27020851"]}}